H.C. Wainwright on Compass Therapeutics (CMPX): 'we do believe the probability of a path forward is meaningfully higher than the market reaction observed'
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $24.00 price target on Compass Therapeutics (NASDAQ: CMPX)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
